{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:47:37Z","timestamp":1792205257421,"version":"4.4.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T00:00:00Z","timestamp":1615334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The World Health Organization recommends intravenous amikacin for the treatment of MDR-TB at a dose of 15\u2009mg\/kg. However, higher doses are associated with significant toxicity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients with MDR-TB treated at our institution receive amikacin at 8\u201310\u2009mg\/kg, with dose adjustment based on therapeutic drug monitoring. We conducted a retrospective cohort study of patients with MDR-TB who received amikacin between 2010 and 2016.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Forty-nine patients were included in the study. The median starting dose of amikacin was 8.9\u2009mg\/kg (IQR 8, 10), and target therapeutic drug levels were achieved at a median of 12\u2009days (IQR 5, 26). The median duration of amikacin treatment was 7.2\u2009months (IQR 5.7, 8), and median time to sputum culture conversion was 1\u2009month (IQR 1,2). Six patients (12.2%) experienced hearing loss based on formal audiometry testing (95% CI 4.6\u201324.8%); 22.2% had subjective hearing loss (95% CI 11.2\u201337.1%) and 31.9% subjective tinnitus (95% CI 19.1\u201347.1%). Ten patients (23%) had a significant rise in serum creatinine (95% CI 11.8\u201338.6%), but only 5 patients had a GFR &lt;\u200960 at treatment completion. 84% of patients had a successful treatment outcome (95% CI 84\u201399%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Low dose amikacin is associated with relatively low rates of aminoglycoside-related adverse events. We hypothesize that low-dose amikacin can be used as a safe and effective treatment for MDR-TB in situations where an adequate regimen cannot be constructed with Group A and B drugs, and where careful monitoring for adverse events is feasible.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-05947-6","type":"journal-article","created":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T11:04:04Z","timestamp":1615374244000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Low-dose amikacin in the treatment of Multidrug-resistant Tuberculosis (MDR-TB)"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9823-9308","authenticated-orcid":false,"given":"Natasha F.","family":"Sabur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mantaj S.","family":"Brar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K.","family":"Brode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,10]]},"reference":[{"key":"5947_CR1","volume-title":"Global tuberculosis report 2019.","author":"WHO","year":"2019","unstructured":"WHO. Global tuberculosis report 2019. Geneva: World Health Organization; 2019."},{"key":"5947_CR2","volume-title":"WHO consolidated guidelines on drug-resistant tuberculosis","author":"WHO","year":"2019","unstructured":"WHO. WHO consolidated guidelines on drug-resistant tuberculosis. Geneva: World Health Organization; 2019."},{"key":"5947_CR3","volume-title":"Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update","author":"WHO","year":"2008","unstructured":"WHO. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update. Geneva: World Health Organization; 2008."},{"issue":"suppl_3","key":"5947_CR4","doi-asserted-by":"publisher","first-page":"S303","DOI":"10.1093\/cid\/ciy613","volume":"67","author":"MGG Sturkenboom","year":"2018","unstructured":"Sturkenboom MGG, Simbar N, Akkerman OW, Ghimire S, Bolhuis MS, Alffenaar JC, et al. Clin Infect Dis. 2018;67(suppl_3):S303\u20137.","journal-title":"Clin Infect Dis"},{"key":"5947_CR5","doi-asserted-by":"crossref","unstructured":"Peloquin C. The Role of Therapeutic Drug Monitoring in Mycobacterial Infections. Microbiol Spectr. 2017;5(1):1\u20138.","DOI":"10.1128\/microbiolspec.TNMI7-0029-2016"},{"key":"5947_CR6","doi-asserted-by":"crossref","unstructured":"van Altena R, Dijkstra JA, van der Meer ME, Borjas Howard JF, Kosterink JG, van Soolingen D, van der Werf TS, Alffenaar JW. Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother. 2017;61(3):1400\u201316.","DOI":"10.1128\/AAC.01400-16"},{"issue":"4","key":"5947_CR7","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","volume":"175","author":"DE Griffith","year":"2007","unstructured":"Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, et al. An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367\u2013416.","journal-title":"Am J Respir Crit Care Med"},{"key":"5947_CR8","unstructured":"Dosing and administration of parenteral aminoglycosides [https:\/\/www.uptodate.com\/contents\/dosing-and-administration-of-parenteral-aminoglycosides?search=aminoglycosides&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2#references]."},{"issue":"3","key":"5947_CR9","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ijantimicag.2006.04.015","volume":"28","author":"JM Conil","year":"2006","unstructured":"Conil JM, Georges B, Breden A, Segonds C, Lavit M, Seguin T, Coley N, Samii K, Chabanon G, Houin G, et al. Increased amikacin dosage requirements in burn patients receiving a once-daily regimen. Int J Antimicrob Agents. 2006;28(3):226\u201330.","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"5947_CR10","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1016\/j.burns.2017.05.009","volume":"43","author":"C Lee","year":"2017","unstructured":"Lee C, Walker SAN, Walker SE, Seto W, Simor A, Jeschke M. A prospective study evaluating tobramycin pharmacokinetics and optimal once daily dosing in burn patients. Burns. 2017;43(8):1766\u201374.","journal-title":"Burns"},{"issue":"1","key":"5947_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s40268-016-0165-5","volume":"17","author":"H Kato","year":"2017","unstructured":"Kato H, Hagihara M, Hirai J, Sakanashi D, Suematsu H, Nishiyama N, Koizumi Y, Yamagishi Y, Matsuura K, Mikamo H. Evaluation of Amikacin pharmacokinetics and pharmacodynamics for optimal initial dosing regimen. Drugs R D. 2017;17(1):177\u201387.","journal-title":"Drugs R D"},{"issue":"6","key":"5947_CR12","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1128\/AAC.33.6.797","volume":"33","author":"RE Brummett","year":"1989","unstructured":"Brummett RE, Fox KE. Aminoglycoside-induced hearing loss in humans. Antimicrob Agents Chemother. 1989;33(6):797\u2013800.","journal-title":"Antimicrob Agents Chemother"},{"key":"5947_CR13","first-page":"11","volume":"34","author":"American Speech-Language-Hearing Association audiologic management of individuals receiving cochleotoxic drug therapy","year":"1994","unstructured":"American Speech-Language-Hearing Association audiologic management of individuals receiving cochleotoxic drug therapy. Guidelines for audiologic management of individuals receiving cochleotoxic drug therapy. ASHA. 1994;34:11\u20139.","journal-title":"ASHA"},{"key":"5947_CR14","volume-title":"Definitions and reporting framework for tuberculosis - 2013 revision","author":"WHO","year":"2013","unstructured":"WHO. Definitions and reporting framework for tuberculosis - 2013 revision. Geneva: World Health Organization; 2013."},{"issue":"3","key":"5947_CR15","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1128\/AAC.35.3.399","volume":"35","author":"DN Gilbert","year":"1991","unstructured":"Gilbert DN. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother. 1991;35(3):399\u2013405.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"5947_CR16","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1093\/jac\/39.6.677","volume":"39","author":"CD Freeman","year":"1997","unstructured":"Freeman CD, Nicolau DP, Belliveau PP, Nightingale CH. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother. 1997;39(6):677\u201386.","journal-title":"J Antimicrob Chemother"},{"issue":"10150","key":"5947_CR17","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","volume":"392","author":"N Ahmad","year":"2018","unstructured":"Collaborative Group for the Meta-Analysis of Individual Patient Data in MDRTBt, Ahmad N, Ahuja SD, Akkerman OW, Alffenaar JC, Anderson LF, Baghaei P, Bang D, Barry PM, Bastos ML, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018;392(10150):821\u201334.","journal-title":"Lancet"},{"key":"5947_CR18","doi-asserted-by":"crossref","unstructured":"Dijkstra JA, van der Laan T, Akkerman OW, Bolhuis MS, de Lange WCM, Kosterink JGW, van der Werf TS, Alffenaar JWC, van Soolingen D. In Vitro Susceptibility of Mycobacterium tuberculosis to Amikacin, Kanamycin, and Capreomycin. Antimicrob Agents Chemother. 2018;62(3):1724\u201317.","DOI":"10.1128\/AAC.01724-17"},{"issue":"10","key":"5947_CR19","doi-asserted-by":"publisher","first-page":"5922","DOI":"10.1128\/AAC.00961-16","volume":"60","author":"S Srivastava","year":"2016","unstructured":"Srivastava S, Modongo C, Siyambalapitiyage Dona CW, Pasipanodya JG, Deshpande D, Gumbo T. Amikacin optimal exposure targets in the hollow-fiber system model of tuberculosis. Antimicrob Agents Chemother. 2016;60(10):5922\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"5947_CR20","first-page":"41","volume-title":"Drug-Resistant Tuberculosis: A Survival Guide for Clinicians","author":"Curry International Tuberculosis Center and California Department of Public Health","year":"2016","unstructured":"Curry International Tuberculosis Center and California Department of Public Health. Drug-Resistant Tuberculosis: A Survival Guide for Clinicians. 3rd ed; 2016. p. 41\u20132.","edition":"3"},{"issue":"1","key":"5947_CR21","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1128\/AAC.39.1.264","volume":"39","author":"C Santre","year":"1995","unstructured":"Santre C, Georges H, Jacquier JM, Leroy O, Beuscart C, Buguin D, Beaucaire G. Amikacin levels in bronchial secretions of 10 pneumonia patients with respiratory support treated once daily versus twice daily. Antimicrob Agents Chemother. 1995;39(1):264\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"5947_CR22","first-page":"622","volume":"6","author":"P de Jager","year":"2002","unstructured":"de Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis. 2002;6(7):622\u20137.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"8","key":"5947_CR23","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1093\/jac\/dkr221","volume":"66","author":"A Sturdy","year":"2011","unstructured":"Sturdy A, Goodman A, Jose RJ, Loyse A, O'Donoghue M, Kon OM, Dedicoat MJ, Harrison TS, John L, Lipman M, et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice. J Antimicrob Chemother. 2011;66(8):1815\u201320.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"5947_CR24","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1086\/420742","volume":"38","author":"CA Peloquin","year":"2004","unstructured":"Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, Iseman MD, Cook JL, Curran-Everett D. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis. 2004;38(11):1538\u201344.","journal-title":"Clin Infect Dis"},{"key":"5947_CR25","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1186\/1471-2334-14-542","volume":"14","author":"C Modongo","year":"2014","unstructured":"Modongo C, Sobota RS, Kesenogile B, Ncube R, Sirugo G, Williams SM, Zetola NM. Successful MDR-TB treatment regimens including amikacin are associated with high rates of hearing loss. BMC Infect Dis. 2014;14:542.","journal-title":"BMC Infect Dis"},{"issue":"6","key":"5947_CR26","doi-asserted-by":"publisher","first-page":"667","DOI":"10.5588\/ijtld.17.0830","volume":"22","author":"H Hong","year":"2018","unstructured":"Hong H, Budhathoki C, Farley JE. Increased risk of aminoglycoside-induced hearing loss in MDR-TB patients with HIV coinfection. Int J Tuberc Lung Dis. 2018;22(6):667\u201374.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"5947_CR27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2174\/138161207779313731","volume":"13","author":"E Selimoglu","year":"2007","unstructured":"Selimoglu E. Aminoglycoside-induced ototoxicity. Curr Pharm Des. 2007;13(1):119\u201326.","journal-title":"Curr Pharm Des"},{"issue":"10","key":"5947_CR28","doi-asserted-by":"publisher","first-page":"6337","DOI":"10.1128\/AAC.01050-15","volume":"59","author":"C Modongo","year":"2015","unstructured":"Modongo C, Pasipanodya JG, Zetola NM, Williams SM, Sirugo G, Gumbo T. Amikacin concentrations predictive of ototoxicity in multidrug-resistant tuberculosis patients. Antimicrob Agents Chemother. 2015;59(10):6337\u201343.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6 Pt 2","key":"5947_CR29","doi-asserted-by":"publisher","first-page":"363","DOI":"10.7196\/SAMJ.4964","volume":"102","author":"T Harris","year":"2012","unstructured":"Harris T, Bardien S, Schaaf HS, Petersen L, De Jong G, Fagan JJ. Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients. S Afr Med J. 2012;102(6 Pt 2):363\u20136.","journal-title":"S Afr Med J"},{"key":"5947_CR30","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1472-6815-7-5","volume":"7","author":"P Duggal","year":"2007","unstructured":"Duggal P, Sarkar M. Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up. BMC Ear Nose Throat Disord. 2007;7:5.","journal-title":"BMC Ear Nose Throat Disord"},{"key":"5947_CR31","doi-asserted-by":"publisher","first-page":"937861","DOI":"10.1155\/2011\/937861","volume":"2011","author":"ME Huth","year":"2011","unstructured":"Huth ME, Ricci AJ, Cheng AG. Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int J Otolaryngol. 2011;2011:937861.","journal-title":"Int J Otolaryngol"},{"key":"5947_CR32","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3389\/fncel.2017.00308","volume":"11","author":"M Jiang","year":"2017","unstructured":"Jiang M, Karasawa T, Steyger PS. Aminoglycoside-induced Cochleotoxicity: a review. Front Cell Neurosci. 2017;11:308.","journal-title":"Front Cell Neurosci"},{"issue":"3","key":"5947_CR33","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40264-015-0267-y","volume":"38","author":"G Ramachandran","year":"2015","unstructured":"Ramachandran G, Swaminathan S. Safety and tolerability profile of second-line anti-tuberculosis medications. Drug Saf. 2015;38(3):253\u201369.","journal-title":"Drug Saf"},{"issue":"12","key":"5947_CR34","first-page":"1314","volume":"11","author":"SS Shin","year":"2007","unstructured":"Shin SS, Pasechnikov AD, Gelmanova IY, Peremitin GG, Strelis AK, Mishustin S, Barnashov A, Karpeichik Y, Andreev YG, Golubchikova VT, et al. Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia. Int J Tuberc Lung Dis. 2007;11(12):1314\u201320.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"5947_CR35","doi-asserted-by":"publisher","first-page":"e57719","DOI":"10.1371\/journal.pone.0057719","volume":"8","author":"PC Chan","year":"2013","unstructured":"Chan PC, Huang SH, Yu MC, Lee SW, Huang YW, Chien ST, Lee JJ, Taiwan multidrug-resistant tuberculosis consortium T. Effectiveness of a government-organized and hospital-initiated treatment for multidrug-resistant tuberculosis patients--a retrospective cohort study. PLoS One. 2013;8(2):e57719.","journal-title":"PLoS One"},{"key":"5947_CR36","doi-asserted-by":"crossref","unstructured":"Anderson LF, Tamne S, Watson JP, Cohen T, Mitnick C, Brown T, Drobniewski F, Abubakar I. Treatment outcome of multi-drug resistant tuberculosis in the United Kingdom: retrospective-prospective cohort study from 2004 to 2007. Euro Surveill. 2013;18(40):1\u201310.","DOI":"10.2807\/1560-7917.ES2013.18.40.20601"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-05947-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-021-05947-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-05947-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T11:06:24Z","timestamp":1615374384000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-05947-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,10]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5947"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-05947-6","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,10]]},"assertion":[{"value":"2 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained from the West Park Healthcare Centre Research and Ethics Board. The need for consent was waived by our Institutional Review Board (REB number 18\u2013010-P).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"254"}}